Showing 15 posts of 194 posts found.


Gilead will give 11 years’ worth of PrEP drugs to those at risk of HIV after ‘discussions’ with Trump

May 10, 2019
Medical Communications Gilead, HIV, PrEP, Trump, Truvada, descovy

Gilead Sciences has agreed to donate 11 years’ worth PrEP drugs for up to 200,000 individuals each year, following “discussions …


HIV cannot be transmitted when viral load is undetectable, study shows

May 3, 2019
Medical Communications Art, HIV, U=U, anti-retroviral drugs, infectious diseases, pharma

The risk of transmitting HIV through gay sex when the infected partner’s HIV load has been fully supressed by antiretroviral …

Doctors cure ‘bubble boy syndrome’ using modified version of HIV

April 18, 2019
Research and Development HIV, SCID-X1, gene therapy, immunodeficiency, immunology

Doctors at St. Jude Children’s Research Hospital have been able to treat patients with X-linked severe combined immunodeficiency (SCID-X1) – …


Janssen’s Symtuza around 90% effective in achieving undetectable HIV-1 viral loads, when used immediately following diagnosis

April 12, 2019
Medical Communications HIV, Janssen, Symtuza, pharma

Janssen has lifted the curtain on data from the first Phase 3 trial investigating the efficacy of Symtuza (darunavir 800mg, …

ViiV Healthcares scores first twin-drug FDA approval for untreated HIV-1

April 9, 2019
Manufacturing and Production, Research and Development GSK, HIV, ViiV Healthcare, pharma

ViiV Healthcare, the pharmaceutical firm owned by Shionogi, Pfizer and predominantly GSK, has announced its two-drug HIV regimen Dovato (dolutegravir …

Gilead accused of ripping off US taxpayers

March 28, 2019
Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents

Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …


Top Ten most popular articles on this week!

March 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Gilead, HIV, Novartis, Scott Gottlieb, top 10

HIV hit the headlines this week after it was announced that a British man known only as the ‘London Patient’ …

Monthly injections offer similar efficacy to daily pills in HIV phase 3 trials

March 8, 2019
Medical Communications ATLAS, GSK, HIV, ViiV, flair, injectable

A long acting, injectable two drug regimen developed by Pfizer and GSK joint venture ViiV Healthcare and J&J subsidiary Jannsen, …


Gilead’s Biktarvy maintains HIV suppression for 48 weeks in children and adolescents

March 7, 2019
Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has lifted the curtain on new Phase 2/3 efficacy data for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 …


Scottish biotech secures initial orders for HIV diagnosis kit from Indonesia, Moldova and Papua New Guinea

March 7, 2019
Business Services, Medical Communications, Research and Development, Sales and Marketing Diagnostics, HIV, Indonesia, Moldova, Scotland, developing coutnries

A small biotech based in Clackmannanshire, Scotland expects to turnover an additional £20 million from sales of its HIV diagnostics …


London man becomes second in world to be cured of HIV

March 5, 2019
Manufacturing and Production Berlin Patient, CCR5, HIV, He Jiankui, London Patient

A man in Britain has become the second person in the world to be ‘cured’ of HIV, after receiving a …

Genetically modified twins may have been altered in a way that improves memory and cognition

February 22, 2019
Medical Communications CCR5, HIV, cognitive enhancement, crispr, gene editing

The twins who were genetically modified using the gene editing tool CRISPR may have been changed in a way that …

Researchers develop new, more effective method for detection of HIV virus genomes

February 8, 2019
Medical Communications, Research and Development HIV, University of Texas, pharma

A team of researchers have devised a new way to accurately detect residual HIV in the body’s immune cells, allowing …

Latest content